CN102639700A - 通过调节自噬增强基因产物调节自噬的方法 - Google Patents

通过调节自噬增强基因产物调节自噬的方法 Download PDF

Info

Publication number
CN102639700A
CN102639700A CN2010800542999A CN201080054299A CN102639700A CN 102639700 A CN102639700 A CN 102639700A CN 2010800542999 A CN2010800542999 A CN 2010800542999A CN 201080054299 A CN201080054299 A CN 201080054299A CN 102639700 A CN102639700 A CN 102639700A
Authority
CN
China
Prior art keywords
autophagy
gene
disease
genes
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800542999A
Other languages
English (en)
Chinese (zh)
Inventor
袁君英
M·M·利平斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of CN102639700A publication Critical patent/CN102639700A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
CN2010800542999A 2009-09-30 2010-09-30 通过调节自噬增强基因产物调节自噬的方法 Pending CN102639700A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24730909P 2009-09-30 2009-09-30
US24725109P 2009-09-30 2009-09-30
US61/247,251 2009-09-30
US61/247,309 2009-09-30
PCT/US2010/050968 WO2011041584A2 (en) 2009-09-30 2010-09-30 Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products

Publications (1)

Publication Number Publication Date
CN102639700A true CN102639700A (zh) 2012-08-15

Family

ID=43365297

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800542999A Pending CN102639700A (zh) 2009-09-30 2010-09-30 通过调节自噬增强基因产物调节自噬的方法
CN2010800543027A Pending CN102869775A (zh) 2009-09-30 2010-09-30 通过调节自噬抑制基因产物调节自噬的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010800543027A Pending CN102869775A (zh) 2009-09-30 2010-09-30 通过调节自噬抑制基因产物调节自噬的方法

Country Status (11)

Country Link
US (4) US20120301463A1 (enExample)
EP (2) EP2483407A2 (enExample)
JP (3) JP2013506687A (enExample)
KR (1) KR20120082906A (enExample)
CN (2) CN102639700A (enExample)
AU (2) AU2010300531A1 (enExample)
BR (2) BR112012007160A2 (enExample)
CA (2) CA2774999A1 (enExample)
MX (1) MX2012003770A (enExample)
RU (1) RU2012117230A (enExample)
WO (2) WO2011041582A2 (enExample)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103877103A (zh) * 2013-04-28 2014-06-25 中国人民解放军军事医学科学院放射与辐射医学研究所 Plcg1基因及其特异性抑制剂u73122抗辐射损伤的新用途
CN103990126A (zh) * 2013-02-17 2014-08-20 复旦大学 一种治疗肿瘤的增效药物组合物
CN104826113A (zh) * 2014-02-12 2015-08-12 中国科学院上海生命科学研究院 抑制间充质干细胞自噬在自身免疫性疾病中的应用
CN109420173A (zh) * 2017-08-31 2019-03-05 清华大学 Gpr55及其调节剂在防治免疫系统疾病中的应用
CN109420174A (zh) * 2017-08-31 2019-03-05 清华大学 Gpr18及其调节剂在防治免疫系统疾病中的应用
CN110283766A (zh) * 2019-05-13 2019-09-27 华中科技大学 一种重组卡介苗及其构建与应用
CN112384241A (zh) * 2018-05-31 2021-02-19 善萃科思生物科技公司 包含cd300c表达抑制剂或活性抑制剂的预防或治疗癌症的药物组合物
CN114761570A (zh) * 2019-08-16 2022-07-15 詹森生物科技公司 具有改善的功能的治疗性免疫细胞及其制备方法
CN115068614A (zh) * 2021-03-12 2022-09-20 胡晓兰 用于诊断、治疗和预防癌症的方法和组合物
CN115814080A (zh) * 2022-12-12 2023-03-21 安徽科技学院 一种含隐丹参酮的光动力治疗剂及其应用

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8187802B2 (en) * 2008-11-19 2012-05-29 Rutgers, The State University Of New Jersey Cell lines useful for assessing modulation of autophagy
AU2013302799B2 (en) 2012-08-13 2018-03-01 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
WO2014093746A2 (en) * 2012-12-14 2014-06-19 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of ckap5 by double-stranded rna
US20160136123A1 (en) * 2013-06-14 2016-05-19 Vojo P. Deretic Treatment of autophagy-related disorders
US20160272969A1 (en) * 2013-10-31 2016-09-22 Ilana (Helena) NATHAN Compositions and methods for modulating autophagic cell death
WO2016054591A1 (en) 2014-10-03 2016-04-07 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
EP3067422B1 (en) * 2015-03-13 2024-07-31 Sabanci Üniversitesi Ct-1 inhibitors
KR101524426B1 (ko) * 2015-03-25 2015-05-29 경희대학교 산학협력단 자가포식 특이적 억제제 발굴을 위한 스크리닝 방법
EP3991748A3 (en) 2015-04-07 2022-08-24 Alector LLC Anti-sortilin antibodies and methods of use thereof
US10849992B1 (en) 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
JP2017214302A (ja) * 2016-05-30 2017-12-07 国立大学法人 東京大学 オートファジー誘導剤
SI3555132T1 (sl) 2016-12-19 2024-04-30 Medimmune Limited Protitelesa proti LIF in njihove uporabe
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
CA3059910A1 (en) 2017-04-19 2018-10-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
WO2019152549A1 (en) 2018-02-05 2019-08-08 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and y-rnas
CN108396036B (zh) * 2018-03-01 2021-08-03 昆明医科大学 一种过表达cox5a转基因鼠模型及其构建方法与应用
WO2019195519A1 (en) * 2018-04-06 2019-10-10 Ionis Pharmaceuticals, Inc. Methods of modulating antisense activity
WO2019231188A1 (ko) * 2018-05-31 2019-12-05 주식회사 센트릭스바이오 Cd300c의 발현 억제제 또는 활성 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물
PT3618928T (pt) 2018-07-13 2023-03-29 Alector Llc Anticorpos anti-sortilina e métodos de utilização dos mesmos
CN109481683B (zh) * 2018-12-19 2021-07-02 四川大学华西医院 α受体阻滞剂在制备治疗急性胰腺炎的药物中的应用
CN109628451A (zh) * 2019-01-10 2019-04-16 广西大学 一种抑制兔Deptor基因表达的shRNA、慢病毒表达载体及其构建方法和应用
CN110106182B (zh) * 2019-05-13 2023-01-10 华南农业大学 p65基因在猪卵巢颗粒细胞中的应用
CN110354131A (zh) * 2019-08-27 2019-10-22 刘磊 阿夫唑嗪在治疗或预防帕金森病及相关疾病中的用途
KR102464507B1 (ko) * 2019-11-18 2022-11-09 주식회사 센트릭스바이오 항-CD300c 단클론 항체를 포함하는 암 예방 또는 치료용 조성물
AU2020387199B2 (en) * 2019-11-18 2025-05-22 CentricsBio, Inc. Composition for preventing or treating cancer, comprising anti-CD300c monoclonal antibodies
US12616734B2 (en) 2019-11-28 2026-05-05 CentricsBio, Inc. Chimeric antigen receptor specifically binding to cd 300C antigen or receptor thereof
CN110850088B (zh) * 2019-12-06 2021-08-20 四川大学华西医院 Gtf2ird2自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
KR102583540B1 (ko) * 2021-01-26 2023-10-06 한국과학기술연구원 퇴행성 뇌질환에서 zbtb16의 용도
WO2022163959A1 (ko) * 2021-01-26 2022-08-04 한국과학기술연구원 퇴행성 뇌질환에서 zbtb16의 용도
CN113077841B (zh) * 2021-03-01 2022-05-24 华中科技大学 一种预测调控酵母自噬的功能基因的方法
KR20220155554A (ko) * 2021-05-13 2022-11-23 주식회사 센트릭스바이오 항-CD300c 항체를 이용한 병용 요법
US20250025487A1 (en) * 2021-07-01 2025-01-23 Cedars-Sinai Medical Center Therapeutic nucleic acids and methods of use thereof
CN114702552B (zh) * 2022-03-11 2024-05-31 苏州思萃免疫技术研究所有限公司 mTORC2抑制剂
EP4520770A4 (en) * 2022-05-02 2026-04-22 Centricsbio Inc Anti-CD300C antibody or antigen-binding fragment thereof, and its uses in preventing or treating neurodegenerative brain disease
CN116609528B (zh) * 2023-04-19 2026-05-12 华南理工大学 一种胰腺癌早期诊断标志物纽扣蛋白cingulin及抗癌药物新靶标

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050276809A1 (en) * 2004-04-30 2005-12-15 Baehrecke Eric H Function of autophagy genes in cell death
WO2008113100A1 (en) * 2007-03-16 2008-09-25 Novogen Research Pty Ltd Method for inducing autophagy

Family Cites Families (263)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6214334B1 (en) 1991-10-21 2001-04-10 Trustees Of The University Of Pennsylvania Compositions and methods for producing and using homogenous neuronal cell transplants to treat neurodegenerative disorders and brain and spinal cord injuries
US5681747A (en) 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU687010B2 (en) 1992-07-17 1998-02-19 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
DE4239877C1 (de) 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
WO1995003832A1 (en) 1993-07-30 1995-02-09 Thomas Jefferson University Intracellular immunization
FR2721943B1 (fr) 1994-06-29 1996-08-02 Rhone Poulenc Rorer Sa Adenovirus comprenant un gene codant pour une superoxyde dismutase
US5556837A (en) 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US5783683A (en) 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US5853987A (en) 1995-04-24 1998-12-29 The Texas A & M University System Decorin binding protein compositions and methods of use
US5834457A (en) 1996-01-26 1998-11-10 The Regents Of The University Of California Method of modulating radical formation by mutant cuznsod enzymes
CA2284039A1 (en) 1997-03-18 1998-09-24 Ortho-Mcneil Pharmaceutical, Inc. Methods and kits for treating and diagnosing leiomyomas
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
US6723694B1 (en) 1997-05-21 2004-04-20 The Children's Medical Center Corp. Short peptides which selectively modulate intracellular signalling
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6096778A (en) 1997-10-07 2000-08-01 Cephalon, Inc. α-ketoamide multicatalytic protease inhibitors
US20010006793A1 (en) 1998-03-20 2001-07-05 Mary-Ann Bjornsti Modulators of eukaryotic caspases
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
EP1087782A4 (en) 1998-06-15 2001-09-12 Neuronz Ltd REGULATION OF TYROSINE HYDROXYLASE
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6319905B1 (en) 1998-12-29 2001-11-20 Cell Genesys, Inc. Method of controlling L-Dopa production and of treating dopamine deficiency
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
US6312949B1 (en) 1999-03-26 2001-11-06 The Salk Institute For Biological Studies Regulation of tyrosine hydroxylase expression
US6297238B1 (en) 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US20030125276A1 (en) 2001-11-08 2003-07-03 Isis Pharmaceuticals Inc. Antisense modulation of thyroid hormone receptor interactor 6 expression
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US6797720B2 (en) 1999-12-03 2004-09-28 Ono Pharmaceutical Co., Ltd. 1,3,4-oxadiazoline derivative and an agent comprising its derivative as active ingredient
WO2001044214A1 (en) 1999-12-03 2001-06-21 Ono Pharmaceutical Co., Ltd. Oxadiazole derivatives and drugs containing these derivatives as the active ingredient
US6334998B1 (en) 1999-12-07 2002-01-01 Parker Hughes Institute Estrogens for treating ALS
CA2395520A1 (en) 1999-12-21 2001-06-28 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
US7108984B2 (en) 2000-01-12 2006-09-19 Mount Sinai School Of Medicine Methods of identifying modulators of the FGF receptor
US20020081663A1 (en) 2000-01-05 2002-06-27 Conklin Darrell C. Novel FGF homolog ZFGF11
AU2001228810A1 (en) 2000-01-26 2001-08-07 Ono Pharmaceutical Co. Ltd. Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient
JP2001292778A (ja) 2000-04-11 2001-10-23 Inst Of Physical & Chemical Res トランケート型リーリンタンパク質およびそれをコードするｄｎａ
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
US20030211967A1 (en) 2001-05-07 2003-11-13 Bryant Henry Uhlman Method for selectively inhibiting ghrelin action
US6967237B2 (en) 2000-05-30 2005-11-22 Merck & Co., Inc. Ghrelin analogs
WO2002000853A2 (en) 2000-06-26 2002-01-03 Bayer Aktiengesellschaft Regulation of human caspase-1-like protease
JP2002017361A (ja) 2000-07-04 2002-01-22 Inst Of Physical & Chemical Res リーリンタンパク質ｃｒ−５０エピトープ領域
JP4409135B2 (ja) * 2000-12-01 2010-02-03 武田薬品工業株式会社 生理活性物質含有製剤の製造法
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
JPWO2002077226A1 (ja) 2001-03-23 2004-07-15 小野薬品工業株式会社 プロスタグランジンｅｐ１受容体
WO2002083131A1 (en) 2001-04-13 2002-10-24 The Regents Of The University Of California Activators and ligands of ppar-beta/delta for the treatment of skin conditions
AU2002256359A1 (en) 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
US20050182006A1 (en) 2001-05-18 2005-08-18 Sirna Therapeutics, Inc RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA)
JPWO2002096892A1 (ja) 2001-05-31 2004-09-09 小野薬品工業株式会社 オキサジアゾール誘導体化合物およびその化合物を有効成分とする薬剤
US7736677B2 (en) 2001-06-20 2010-06-15 Metaproteomics, Llc Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
AU2002315393A1 (en) 2001-06-21 2003-01-08 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
CA2452578A1 (en) 2001-07-03 2003-01-16 The Hospital For Sick Children Ephrin and eph receptor mediated immune modulation
DE10134196B4 (de) 2001-07-13 2005-08-18 Forschungszentrum Karlsruhe Gmbh Technik Und Umwelt Pharmazeutische Zusammensetzung zur Hemmung der unkontrollierten Vermehrung und/oder Induzierung der Apoptose von Zellen
US7348140B1 (en) 2001-07-25 2008-03-25 Acadia Pharmaceuticals, Inc. Clinical indications for genotyping polymorphic variants of G-protein coupled receptors
DE60230877D1 (de) 2001-08-15 2009-03-05 Univ Brown Res Found Behandlung von muskeldystrophien und verwandter erkrankungen
WO2003016343A2 (en) 2001-08-16 2003-02-27 Angiogene Inc. USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS
AU2002324937B2 (en) 2001-09-07 2008-11-13 The Trustees Of Boston Univeristy Method and composition for treating immune complex associated disorders
EP1451581A4 (en) 2001-10-05 2006-01-11 Coley Pharm Gmbh AGONISTS AND ANTAGONISTS OF THE SIGNALING OF THE GREAT-SIMILAR RECEPTOR 3
US20030078199A1 (en) 2001-10-09 2003-04-24 Youmin Shu Human EphA6 gene and polypeptide
JP4276074B2 (ja) 2001-10-12 2009-06-10 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体δの活性化剤
EP1442062A4 (en) 2001-10-18 2005-11-09 Genentech Inc METHOD FOR TREATING CARCINOMA
CA2464887A1 (en) 2001-10-30 2003-05-08 Biogen, Inc. Methods and compositions for treating parkinson's disease
KR100898894B1 (ko) 2001-11-05 2009-05-21 메르크 파텐트 게엠베하 히드라조노-말로니트릴
US20030165485A1 (en) 2001-11-09 2003-09-04 Goran Bertilsson Functional role and potential therapeutic use of Reelin, Gas6 and Protein S in relation to adult neural stem or progenitor cells
WO2003047511A2 (en) 2001-11-29 2003-06-12 U.S. Department Of Veterans Affairs Use of gingko biloba extracts to promote neuroprotection and reduce weight loss
CN102526045A (zh) 2001-12-06 2012-07-04 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
CN1606451A (zh) 2001-12-19 2005-04-13 伊藤火腿株式会社 构象病的治疗剂和/或预防剂
JP2005530687A (ja) 2002-01-31 2005-10-13 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ Ｆｇｆｒアゴニスト
US20030199525A1 (en) 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
US20030225098A1 (en) 2002-03-21 2003-12-04 Hirst Gavin C. Kinase inhibitors
SI1487541T1 (sl) 2002-03-22 2009-02-28 Serono Lab Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja
AU2003227066A1 (en) 2002-03-26 2003-10-08 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor (ghs)
IL149562A0 (en) 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
ES2615484T3 (es) 2002-05-21 2017-06-07 Daiichi Sankyo Company, Limited Composiciones medicinales que contienen grelina
AU2003238948A1 (en) 2002-06-05 2003-12-22 Sunesis Pharmaceuticals, Inc. Caspase-1 inhibitors and methods for their use
US20040022765A1 (en) 2002-07-31 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of Ran GTPase activating protein 1 expression
AU2003246261A1 (en) 2002-07-05 2004-01-23 Chugai Seiyaku Kabushiki Kaisha Remedy for diabetes
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
EP1530635B1 (en) * 2002-08-01 2011-06-15 Noxxon Pharma AG Ghrelin binding nucleic acids
WO2004013145A1 (en) 2002-08-02 2004-02-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
DE10244453A1 (de) 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
EP1407760A1 (de) 2002-10-08 2004-04-14 Cognis France S.A. Verfahren zum Schutz der Haut gegen Alterung
EP1558640B1 (en) 2002-10-29 2011-04-13 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
ATE443764T1 (de) 2002-11-04 2009-10-15 Univ Massachusetts Allelspezifische rna-interferenz
JP2006507841A (ja) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
JP3810731B2 (ja) 2002-11-29 2006-08-16 独立行政法人科学技術振興機構 哺乳動物のＴｏｌｌ様受容体３に結合する新規アダプタータンパク質およびその遺伝子
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
ATE545429T1 (de) 2002-12-20 2012-03-15 Lundbeck & Co As H Modulation der neurotrophinaktivität;screeningsverfahren
WO2004064713A2 (en) 2003-01-20 2004-08-05 Vib Vzw The use of yop preoteins or rho gtpase inhibitors as caspase-1 inhibitors
US7354933B2 (en) 2003-01-31 2008-04-08 Aventis Pharma Sa Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
CN101444621B (zh) 2003-02-11 2013-11-20 夏尔人类遗传性治疗公司 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
US20040220270A1 (en) 2003-03-07 2004-11-04 The Jackson Laboratory Methods and composition of treating glaucoma by modulating tyrosinase/L-DOPA pathway
CA2522441A1 (en) 2003-03-27 2004-10-14 Emory University Hif-1 inhibitors
US7253166B2 (en) 2003-04-22 2007-08-07 Irm Llc 6-phenyl-7H-pyrrolo[2,3-d]pyrimidine compounds that induce neuronal differentiation in embryonic stem cells
US20040242559A1 (en) 2003-04-25 2004-12-02 Aventis Pharma S.A. Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
ES2383685T3 (es) 2003-04-30 2012-06-25 Kenji Kangawa Preventivos o remedios para hepatopatía
US7423031B2 (en) 2003-05-01 2008-09-09 Irm Llc Compounds and compositions as protein kinase inhibitors
ME00541B (me) 2003-05-23 2011-10-10 Zentaris Gmbh NOVI PIRIDOPIRAZINI I NJlUHOVA UPOTREBA KAO MODULATORA KlNAZA
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US20050002897A1 (en) 2003-06-18 2005-01-06 Ulrich Haupts Biological entities and the pharmaceutical or diagnostic use thereof
JP2007524615A (ja) 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー 低分子トール様レセプター（ｔｌｒ）アンタゴニスト
US8592391B2 (en) 2003-07-01 2013-11-26 Andres Salazar Method for therapeutic, clinical and veterinary use poly-ICLC
US7276608B2 (en) 2003-07-11 2007-10-02 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
DE602004027508D1 (de) 2003-08-07 2010-07-15 Enkam Pharmaceuticals As Lpa-haltige verbindungen
EP2060270A3 (en) 2003-10-16 2009-12-09 Imclone LLC Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
US20080248462A1 (en) 2003-10-21 2008-10-09 Baayer Healhcare Ag Diagnostics and Therapeutics for Diseases Associated with Arginyl Aminopeptidase (Aminopeptidase B)-Like 1 (Rnpepl1)
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
CA2544602A1 (en) 2003-11-04 2005-05-26 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
CA2543315A1 (en) 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
WO2005048916A2 (en) 2003-11-20 2005-06-02 Biovitrum Ab Tetrahydrospiro-beta-carboline-1,3 '-pyrrolidine derivatives and their use in ghsr-related disorders
EP1693070A1 (en) 2003-11-26 2006-08-23 Daiichi Pharmaceutical Co., Ltd. Procaspase 1 activation inhibitor
JP2007513967A (ja) 2003-12-11 2007-05-31 セラヴァンス， インコーポレーテッド 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
HRP20070241T3 (hr) 2003-12-19 2007-07-31 Bristol-Myers Squibb Company Azabiciklički heterocikli kao modulatori kanabinoid receptora
WO2005066211A2 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
EP1704228B1 (en) 2004-01-16 2012-04-11 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immunokinases
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
WO2005074923A1 (en) 2004-02-03 2005-08-18 Agt Biosciences Limited Methods and compositions
EP1720567A2 (en) 2004-02-10 2006-11-15 Innate Pharma Composition and method for the treatment of carcinoma
EP1742961A4 (en) 2004-02-13 2009-07-15 Boston Biomedical Res Inst LOCKING OF FGF SIGNALING
US20060058255A1 (en) 2004-03-01 2006-03-16 Jianzhu Chen RNAi-based therapeutics for allergic rhinitis and asthma
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
EP1730520A2 (en) 2004-03-24 2006-12-13 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with peroxisome proliferator activated receptor delta (ppard)
FR2868422B1 (fr) 2004-03-31 2006-07-14 Aventis Pharma Sa Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
JP2007530703A (ja) 2004-04-01 2007-11-01 アベンティス・ファーマスーティカルズ・インコーポレイテツド Ｍｓおよびその他の脱髄疾患を治療するためのペルオキシソーム増殖因子活性化受容体デルタアゴニストの使用
BRPI0508180A (pt) 2004-04-01 2007-08-07 Aventis Pharma Inc 1,3,4-oxadiazol-2-onas como moduladores de ppar delta e seu uso deste
US7498316B2 (en) 2004-04-06 2009-03-03 University Of Massachusetts Methods and compositions for treating gain-of-function disorders using RNA interference
WO2005099741A1 (ja) 2004-04-08 2005-10-27 Noevir Co., Ltd. 運動ニューロン疾患治療薬
US7357933B2 (en) 2004-05-05 2008-04-15 Enhan Technology Holdings International Co., Ltd. Sporoderm-broken germination-activated ganoderma lucidum spores for protection of dopaminergic neurons and treatment of Parkinson's disease
AU2005245896A1 (en) 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
CA2566362C (en) 2004-05-15 2013-09-10 Vertex Pharmaceuticals Incorporated Treating seizures using ice inhibitors
GB0411791D0 (en) 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
WO2005118587A1 (en) 2004-06-02 2005-12-15 Takeda Pharmaceutical Company Limited Indole derivative and use for treatment of cancer
WO2005120570A2 (en) 2004-06-03 2005-12-22 The University Of Maryland, Baltimore Therapeutic targeting of parc/ccl18 and its signaling in pulmonary fibrosis
AU2005249570B2 (en) 2004-06-04 2011-06-16 Regeneron Pharmaceuticals, Inc. Methods of using IL-1 antagonists to treat autoinflammatory disease
US7102002B2 (en) 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
BRPI0512254A (pt) 2004-06-18 2008-02-19 Enkam Pharmaceuticals As peptìdeos ligantes ao fgfr
WO2006014653A1 (en) 2004-07-20 2006-02-09 Schering Corporation Induction of apoptosis in toll-like receptor expressing tumor cells
EP1621539A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621536A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621535A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
CA2577060A1 (en) 2004-08-13 2006-02-23 Amgen Inc. Substituted benzofused heterocycles
AU2005277641A1 (en) 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
EP1800131A2 (en) 2004-09-09 2007-06-27 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
ES2614113T3 (es) 2004-09-17 2017-05-29 Biomas Ltd. Uso de tricloro (dioxietilen-O,O’) telurato de amonio (AS101) para la inhibición de la enzima convertidora de interleucina-1 beta
FR2876103B1 (fr) 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
CA2586080A1 (en) 2004-11-01 2006-08-31 University Of Southern California Novel compounds for treatment of cancer and disorders associated with angiogenesis function
CA2587676A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
EP1662259A1 (en) 2004-11-25 2006-05-31 Cellzome Ag Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases
AR051836A1 (es) 2004-11-30 2007-02-14 Centocor Inc Antagonistas de receptor 3 simil toll metodos y usos
JP2008521840A (ja) 2004-11-30 2008-06-26 ガストロテック・ファルマ・アクティーゼルスカブ 成長ホルモン分泌促進物質レセプター１ａリガンド
AU2005323173A1 (en) 2004-12-01 2006-07-13 The Curators Of The University Of Missouri Modulator of alpha-synuclein toxicity
DE602005023345D1 (de) 2004-12-17 2010-10-14 Beth Israel Hospital Zusammensetzungen für bakteriell vermitteltes gen-silencing sowie verfahren zur verwendung davon
US7834064B2 (en) 2005-01-03 2010-11-16 Andres Mario Salazar Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs
CA2593648A1 (en) 2005-01-10 2006-07-13 Research Development Foundation Targeted chimeric molecules for cancer therapy
US20060160737A1 (en) 2005-01-14 2006-07-20 Allen Radin Methods of using IL-1 antagonists to treat polymyalgia rheumatica and giant cell arteritis
US20060194821A1 (en) 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
JP2008531502A (ja) 2005-02-22 2008-08-14 ザ レジェンツ オブ ザ ユニバーシティ オブ カリフォルニア 胃腸の炎症を処置する方法
WO2006094124A2 (en) 2005-03-02 2006-09-08 The Scripps Research Institute Compositions and methods for treatment of autoimmune and related diseases
WO2006108270A1 (en) 2005-04-11 2006-10-19 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
WO2006122931A1 (en) 2005-05-20 2006-11-23 Biovitrum Ab (Publ) Beta-carboline derivatives and theri use as ghsr modulators
EP1885181A2 (en) 2005-05-23 2008-02-13 Smithkline Beecham Corporation Inhibition of p38 mark for treatment of obesity
EP1924294A4 (en) 2005-05-24 2010-11-03 Isis Pharmaceuticals Inc COMPOSITIONS AND ITS USES AGAINST PTPRU
BRPI0613515A2 (pt) 2005-07-11 2011-01-11 Cbio Ltd imunomodulação induzida por chaperonina 10
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1937827B1 (en) 2005-08-31 2011-09-28 Université Laval Antibodies and their use in the treatment, prevention and diagnosis of a disease associated with sod1 abnormalities
JP5329961B2 (ja) 2005-09-06 2013-10-30 トリニティー セラピューティクス インコーポレイテッド 免疫介在性神経疾患を治療するための方法
FR2891273B1 (fr) 2005-09-27 2007-11-23 Aventis Pharma Sa NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet
BRPI0616476A2 (pt) 2005-09-30 2011-06-21 Scynexis Inc uso de uma quantidade terapeuticamente eficaz de um derivado de ciclosporina, e, composição farmacêutica
US7598273B2 (en) 2005-10-06 2009-10-06 Auspex Pharmaceuticals, Inc Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties
CN101287742B (zh) 2005-10-12 2016-01-06 艾德拉药物股份有限公司 基于变异应答调制Toll样受体的免疫调节寡核苷酸(IRO)化合物
KR20080075505A (ko) 2005-10-20 2008-08-18 씨바이오 리미티드 과민증의 치료 방법
RU2008119687A (ru) 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений
JP5199878B2 (ja) 2005-10-27 2013-05-15 セントカー・インコーポレーテツド Ｔｏｌｌ様受容体３モジュレーター、方法および用途
ATE530562T1 (de) 2005-10-28 2011-11-15 Janssen Biotech Inc Tlr3-glycosylierungsstandortmuteine und verwendungsverfahren dafür
WO2007058998A2 (en) 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
WO2007062119A1 (en) 2005-11-23 2007-05-31 Auspex Pharmaceuticals, Inc. Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
PT1954669E (pt) 2005-12-01 2015-10-23 Auspex Pharmaceuticals Inc Feniletilaminas substituídas com actividade serotoninérgica e/ou norepinefrinérgica
WO2007087451A2 (en) 2006-01-25 2007-08-02 University Of Massachusetts Compositions and methods for enhancing discriminatory rna interference
CA2638906A1 (en) 2006-01-26 2007-08-16 University Of Massachusetts Rna interference agents for therapeutic use
WO2007090068A2 (en) 2006-01-27 2007-08-09 Fibrogen, Inc. Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif)
AU2007215247B2 (en) 2006-02-10 2012-12-13 Transtech Pharma, Llc Benzazole derivatives, compositions, and methods of use as Aurora kinase inhibitors
EP1986657A4 (en) 2006-02-16 2011-07-20 Discogen Llc METHOD OF TREATING A SUBJECT SUFFERING FROM DEGENERATIVE DISCOPATHY BY A MATRIX METALLOPROTEASE INHIBITOR
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
EP1834953A1 (en) 2006-03-14 2007-09-19 Ranbaxy Laboratories Limited Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors
JP5336349B2 (ja) * 2006-03-15 2013-11-06 マイケル・オー・ソーナー 成長ホルモン分泌促進物質による筋肉減少症の処置方法
US20070232556A1 (en) 2006-03-31 2007-10-04 Montine Thomas J Methods and compositions for the treatment of neurological diseases and disorders
EP2016078B1 (en) 2006-04-04 2016-06-15 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as hif modulators
US20070249519A1 (en) 2006-04-20 2007-10-25 Kalypsys, Inc. Methods for the upregulation of glut4 via modulation of ppar delta in adipose tissue and for the treatment of disease
US8536120B2 (en) 2006-04-28 2013-09-17 The Administrators Of The Tulane Educational Fund Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof
EP2023721A2 (en) 2006-06-05 2009-02-18 Auspex Pharmaceuticals Inc. Preparation and utility of substituted erythromycin analogs
EP2024365A4 (en) 2006-06-05 2010-08-25 Auspex Pharmaceuticals Inc PREPARATION AND UTILITY OF SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS HAVING HYPNOTIC EFFECTS
US20070287734A1 (en) 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
EP2054392A2 (en) 2006-06-15 2009-05-06 Boehringer Ingelheim International GmbH 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase c-alpha
KR20090023698A (ko) 2006-06-15 2009-03-05 베링거 인겔하임 인터내셔날 게엠베하 2-아닐리노-4-아미노알킬렌아미노피리미딘
TW200817023A (en) 2006-06-20 2008-04-16 Metaproteomics Llc Xanthohumol based protein kinase modulation cancer treatment
US8088733B2 (en) 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
US7585865B2 (en) 2006-07-21 2009-09-08 The Penn State Research Foundation Protein kinase C zeta inhibition to treat vascular permeability
WO2008016677A2 (en) 2006-08-02 2008-02-07 Auspex Pharmaceuticals, Inc. Preparation and utility of deuterated amphetamines
AU2007286186A1 (en) 2006-08-08 2008-02-21 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
CA2661302A1 (en) 2006-08-16 2008-02-21 Auspex Pharmaceuticals, Inc. Preparation and utility of opioid analgesics
WO2008026946A2 (en) 2006-08-30 2008-03-06 Genesis Research And Development Corporation Limited Compositions and methods for the treatment and prevention of neoplastic disorders
US20090074711A1 (en) 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
US20080221132A1 (en) 2006-09-11 2008-09-11 Xiong Cai Multi-Functional Small Molecules as Anti-Proliferative Agents
BRPI0715579A2 (pt) 2006-10-19 2015-05-26 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
US9375440B2 (en) 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US20080132555A1 (en) 2006-11-28 2008-06-05 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted phenyltetrazoles
US20080146573A1 (en) 2006-12-04 2008-06-19 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted oxzolidinones
US20080167312A1 (en) 2006-12-08 2008-07-10 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted allylamines
CA2677399C (en) 2007-02-09 2016-09-13 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
WO2008103899A1 (en) 2007-02-23 2008-08-28 Auspex Pharmaceuticals, Inc. Preparation and utility of non-nucleoside reverse transcriptase inhibitors
ES2693948T3 (es) 2007-03-15 2018-12-14 Auspex Pharmaceuticals, Inc. Fenetilamina sustituida con actividad serotoninérgica y/o norepinefrinérgica
WO2008122020A1 (en) 2007-04-02 2008-10-09 Auspex Pharmaceuticals, Inc. Substituted pyrimidines
US7863308B2 (en) 2007-04-10 2011-01-04 Auspex Pharmaceuticals, Inc. Substituted thiophenes
WO2008130863A2 (en) 2007-04-11 2008-10-30 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles
US20080262086A1 (en) 2007-04-18 2008-10-23 Auspex Pharmaceuticals, Inc. Substituted anthranilic acids
CN101765582A (zh) 2007-04-26 2010-06-30 奥斯拜客斯制药有限公司 氘标记的氯胺酮
US20080280991A1 (en) 2007-05-08 2008-11-13 Auspex Pharmaceuticals, Inc. Substituted naphthalenes
US20080280886A1 (en) 2007-05-08 2008-11-13 Auspex Pharmaceuticals, Inc. Substituted ureas
WO2008143835A1 (en) * 2007-05-15 2008-11-27 Yale University Ghrelin protects substantia nigra dopamine neurons
US20090005309A1 (en) 2007-05-18 2009-01-01 Auspex Pharmaceuticals, Inc. Substituted piperidines
WO2008147956A2 (en) 2007-05-25 2008-12-04 Centocor, Inc. Toll-like receptor 3 modulators and uses thereof
US7745665B2 (en) 2007-06-04 2010-06-29 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
AU2008262291A1 (en) 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
US20080312247A1 (en) 2007-06-13 2008-12-18 Auspex Pharmaceuticals, Inc. Substituted piperazines
WO2008152816A1 (en) * 2007-06-14 2008-12-18 Oncotherapy Science, Inc. Methods of identifying agents that modulate methylation of vegfr1 by smyd3
CA2691379C (en) 2007-06-20 2015-06-09 Auspex Pharmaceuticals, Inc. Substituted n-aryl pyridinones
WO2009006413A1 (en) 2007-06-30 2009-01-08 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
EP2193140B1 (en) 2007-08-27 2016-11-02 1Globe Health Institute LLC Compositions of asymmetric interfering rna and uses thereof
US7767860B2 (en) 2007-09-06 2010-08-03 Auspex Pharmaceuticals, Inc Substituted amino alcohols
US20090088401A1 (en) 2007-09-27 2009-04-02 Andres Salazar In-situ cancer autovaccination with intratumoral stabilized dsRNA viral mimic

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050276809A1 (en) * 2004-04-30 2005-12-15 Baehrecke Eric H Function of autophagy genes in cell death
WO2008113100A1 (en) * 2007-03-16 2008-09-25 Novogen Research Pty Ltd Method for inducing autophagy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KOMASTU等: "Impairment of starvation-induced and constitutive autophagy in", 《JCB》, vol. 169, no. 3, 2 May 2005 (2005-05-02) *
李国东等: "细胞自噬在肿瘤中作用的研究进展", 《癌症》, vol. 28, no. 4, 30 April 2009 (2009-04-30), pages 445 - 448 *
高冬梅等: "细胞自噬分子机制以及与肿瘤及肿瘤治疗的研究进展", 《热带病与寄生虫学》, vol. 5, no. 1, 31 March 2007 (2007-03-31), pages 62 - 65 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103990126A (zh) * 2013-02-17 2014-08-20 复旦大学 一种治疗肿瘤的增效药物组合物
CN103877103A (zh) * 2013-04-28 2014-06-25 中国人民解放军军事医学科学院放射与辐射医学研究所 Plcg1基因及其特异性抑制剂u73122抗辐射损伤的新用途
CN104826113A (zh) * 2014-02-12 2015-08-12 中国科学院上海生命科学研究院 抑制间充质干细胞自噬在自身免疫性疾病中的应用
CN104826113B (zh) * 2014-02-12 2018-06-05 中国科学院上海生命科学研究院 抑制间充质干细胞自噬在自身免疫性疾病中的应用
CN109420174B (zh) * 2017-08-31 2021-07-13 清华大学 Gpr18及其调节剂在防治免疫系统疾病中的应用
CN109420174A (zh) * 2017-08-31 2019-03-05 清华大学 Gpr18及其调节剂在防治免疫系统疾病中的应用
CN109420173B (zh) * 2017-08-31 2021-07-13 清华大学 Gpr55及其调节剂在防治免疫系统疾病中的应用
CN109420173A (zh) * 2017-08-31 2019-03-05 清华大学 Gpr55及其调节剂在防治免疫系统疾病中的应用
CN112384241A (zh) * 2018-05-31 2021-02-19 善萃科思生物科技公司 包含cd300c表达抑制剂或活性抑制剂的预防或治疗癌症的药物组合物
CN110283766A (zh) * 2019-05-13 2019-09-27 华中科技大学 一种重组卡介苗及其构建与应用
CN114761570A (zh) * 2019-08-16 2022-07-15 詹森生物科技公司 具有改善的功能的治疗性免疫细胞及其制备方法
CN115068614A (zh) * 2021-03-12 2022-09-20 胡晓兰 用于诊断、治疗和预防癌症的方法和组合物
CN115814080A (zh) * 2022-12-12 2023-03-21 安徽科技学院 一种含隐丹参酮的光动力治疗剂及其应用
CN115814080B (zh) * 2022-12-12 2023-07-07 安徽科技学院 一种含隐丹参酮的光动力治疗剂及其应用

Also Published As

Publication number Publication date
EP2483406A2 (en) 2012-08-08
EP2483407A2 (en) 2012-08-08
BR112012007160A2 (pt) 2018-03-13
BR112012007137A2 (pt) 2015-09-15
WO2011041582A2 (en) 2011-04-07
MX2012003770A (es) 2012-08-03
JP2016040297A (ja) 2016-03-24
JP2013506686A (ja) 2013-02-28
CA2774999A1 (en) 2011-04-07
US20120301463A1 (en) 2012-11-29
US20160194631A1 (en) 2016-07-07
AU2010300531A1 (en) 2012-05-24
US20140004108A1 (en) 2014-01-02
CN102869775A (zh) 2013-01-09
WO2011041582A3 (en) 2011-09-29
RU2012117230A (ru) 2013-11-10
WO2011041584A3 (en) 2011-05-26
AU2016201939A1 (en) 2016-04-21
US20120315244A1 (en) 2012-12-13
KR20120082906A (ko) 2012-07-24
CA2774998A1 (en) 2011-04-07
WO2011041584A2 (en) 2011-04-07
JP2013506687A (ja) 2013-02-28

Similar Documents

Publication Publication Date Title
JP2013506686A (ja) オートファジー阻害遺伝子産物の変調によりオートファジーを変調する方法
JP2021020951A (ja) セロトニン放出ホルモン、アドレナリン放出ホルモン、ノルアドレナリン放出ホルモン、グルタミン酸放出ホルモンおよび副腎皮質刺激ホルモン放出ホルモン関連の医学的状態の処置および診断のためのマイクロｒｎａおよび該マイクロｒｎａを含む組成物
Kindler et al. Dendritic mRNA targeting and translation
US11332540B2 (en) Use of Circ-CDH1 inhibitors
EP3524679A1 (en) Micro-rna mir-19 and compositions comprising same for the treatment of medical conditions in which low adrenaline or noradrenaline level is therapeutically beneficial
Wang et al. Temporal changes in inflammatory mitochondria-enriched microRNAs following traumatic brain injury and effects of miR-146a nanoparticle delivery
US20160160217A1 (en) Compositions and methods for characterizing and treating muscular dystrophy
Gavet et al. Regulation and subcellular localization of the microtubule‐destabilizing stathmin family phosphoproteins in cortical neurons
Ma et al. Overexpression of FER1L4 promotes the apoptosis and suppresses epithelial-mesenchymal transition and stemness markers via activating PI3K/AKT signaling pathway in osteosarcoma cells
Arora et al. Protrudin regulates FAK activation, endothelial cell migration and angiogenesis
Zhang et al. Silencing the epidermal growth factor receptor gene with RNAi may be developed as a potential therapy for non small cell lung cancer
CN103380214B (zh) 用于治疗脑肿瘤的支链氨基转移酶-1(bcat1)抑制剂
CN116256515A (zh) Ppdpf在胆管癌诊断及药物制备中的用途
US20230366033A1 (en) Methods for treating cancers with inhibitors targeting the role of grb2 in dna repair
WO2008027855A2 (en) Compositions and methods for modulating mtor signaling
US9730954B2 (en) miRNAs as novel therapeutic adjuvants and biomarkers for the prognosis and treatment of drug resistant breast cancers
TWI719005B (zh) 細胞死亡誘導劑、細胞增殖抑制劑及起因於細胞增殖異常之疾病治療用醫藥組合物
KR20190054909A (ko) HIF-2α 활성 억제제를 포함하는 연골육종 치료, 전이 또는 재발 억제용 조성물
JP2016518812A (ja) 線維症治療において有用な分子標的及び前記標的のインヒビター
CN120290720B (zh) 靶向RPS4X基因的siRNA、LAMB3-PI3K-AKT信号通路抑制剂、卵巢癌药物及应用
Yang et al. GRK5 Overexpression Drives Malignant Glioma Progression Through HDAC7 Alongside Canonical GPCR Signaling
WO2015187929A1 (en) Treatment of fragile x syndrome by inhibition of cdh1-apc
Bond The Role of FOXD1 in Clear Cell Renal Cell Carcinoma
CN121951040A (zh) 一种用于治疗shh亚型髓母细胞瘤的生物标志物组合
HK40100787A (zh) 调节src-1凝聚体的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120815